• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    11/28/23 8:06:49 AM ET
    $BTTX
    $CWBR
    $CYTO
    $EIGR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $BTTX alert in real time by email

    Gainers

    • Avidity Biosciences (NASDAQ:RNA) shares rose 38.1% to $8.51 during Tuesday's pre-market session. The market value of their outstanding shares is at $630.6 million.
    • Heart Test Laboratories (NASDAQ:HSCS) shares moved upwards by 22.98% to $0.26. The market value of their outstanding shares is at $12.8 million.
    • Redhill Biopharma (NASDAQ:RDHL) shares moved upwards by 17.99% to $1.18. The company's market cap stands at $13.0 million.
    • icad (NASDAQ:ICAD) shares increased by 17.51% to $1.61. The market value of their outstanding shares is at $42.4 million.
    • Virax Biolabs Group (NASDAQ:VRAX) stock moved upwards by 10.81% to $0.25. The market value of their outstanding shares is at $4.5 million.
    • Eiger BioPharmaceuticals (NASDAQ:EIGR) shares increased by 10.78% to $0.34. The company's market cap stands at $15.0 million.

    Losers

    • Tharimmune (NASDAQ:THAR) stock fell 69.5% to $1.07 during Tuesday's pre-market session.
    • SenesTech (NASDAQ:SNES) stock decreased by 38.3% to $1.16.
    • CohBar (NASDAQ:CWBR) shares fell 23.91% to $0.68. The company's market cap stands at $1.9 million.
    • Nexalin Technology (NASDAQ:NXL) shares declined by 13.67% to $0.29. The market value of their outstanding shares is at $2.1 million.
    • Better Therapeutics (NASDAQ:BTTX) stock decreased by 12.51% to $0.17. The market value of their outstanding shares is at $8.0 million.
    • Altamira Therapeutics (NASDAQ:CYTO) stock decreased by 10.48% to $0.2. The market value of their outstanding shares is at $1.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BTTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BTTX
    $CWBR
    $CYTO
    $EIGR

    CompanyDatePrice TargetRatingAnalyst
    Atrium Therapeutics Inc.
    $RNA
    9/17/2025$62.00Buy
    Roth Capital
    Atrium Therapeutics Inc.
    $RNA
    7/10/2025$55.00Buy
    Goldman
    Atrium Therapeutics Inc.
    $RNA
    6/24/2025$50.00Outperform
    Bernstein
    Atrium Therapeutics Inc.
    $RNA
    6/17/2025$55.00Outperform
    Wolfe Research
    Atrium Therapeutics Inc.
    $RNA
    6/11/2025$65.00Strong Buy
    Raymond James
    iCAD Inc.
    $ICAD
    4/17/2025Buy → Neutral
    BTIG Research
    iCAD Inc.
    $ICAD
    4/17/2025Buy → Hold
    Laidlaw
    Virax Biolabs Group Limited
    $VRAX
    3/31/2025$3.00Buy
    H.C. Wainwright
    More analyst ratings

    $BTTX
    $CWBR
    $CYTO
    $EIGR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $200,635 worth of shares (85,901 units at $2.34) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/19/26 7:57:41 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $56,667 worth of shares (31,346 units at $1.81) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/13/26 5:20:17 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $15,480 worth of shares (8,569 units at $1.81) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/6/26 5:40:20 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $BTTX
    $CWBR
    $CYTO
    $EIGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $200,635 worth of shares (85,901 units at $2.34) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/19/26 7:57:41 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $56,667 worth of shares (31,346 units at $1.81) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/13/26 5:20:17 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SEC Form 3 filed by new insider Radkowski Angela Dominy

    3 - Tharimmune, Inc. (0001861657) (Issuer)

    2/11/26 5:20:49 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTTX
    $CWBR
    $CYTO
    $EIGR
    SEC Filings

    View All

    SEC Form PRE 14A filed by HeartSciences Inc.

    PRE 14A - HeartSciences Inc. (0001468492) (Filer)

    3/6/26 5:13:19 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    SEC Form 6-K filed by Redhill Biopharma Ltd.

    6-K - RedHill Biopharma Ltd. (0001553846) (Filer)

    3/5/26 9:00:19 AM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Avidity Biosciences Inc.

    8-K - Avidity Biosciences, Inc. (0001599901) (Filer)

    2/26/26 4:58:13 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTTX
    $CWBR
    $CYTO
    $EIGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on Avidity Biosciences with a new price target

    Roth Capital initiated coverage of Avidity Biosciences with a rating of Buy and set a new price target of $62.00

    9/17/25 7:57:56 AM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman resumed coverage on Avidity Biosciences with a new price target

    Goldman resumed coverage of Avidity Biosciences with a rating of Buy and set a new price target of $55.00

    7/10/25 8:52:40 AM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bernstein initiated coverage on Avidity Biosciences with a new price target

    Bernstein initiated coverage of Avidity Biosciences with a rating of Outperform and set a new price target of $50.00

    6/24/25 7:59:27 AM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTTX
    $CWBR
    $CYTO
    $EIGR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SenesTech to Report Fourth Quarter and Fiscal Year 2025 Financial Results on Thursday, March 12, 2026

    Financial results to be released after market close; Conference call to be conducted at 5:00 p.m. Eastern timePHOENIX, March 9, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, will report financial results for its fourth quarter and fiscal year 2025, ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Company has scheduled a conference call that same day, Thursday, March 12, 2026, at 5:00 pm ET, to review the results. Fourth Quarter and Fiscal Year 2024 Conference Call DetailsDa

    3/9/26 4:15:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsight

    The H. pylori infection market is evolving as treatment strategies shift toward optimized, targeted combination therapies, including triple- and quadruple-drug regimens, bismuth-based therapies, and novel emerging therapies such as Rifasutenizol (TenNor Therapeutics), Linaprazan glurate (Cinclus Pharma), Tegoprazan (RQ-00000004) (RaQualia Pharma/HK inno.N/Sebela Pharmaceuticals), and others, driven by improved eradication rates and safety profiles.LAS VEGAS, March 4, 2026 /PRNewswire/ -- Recently published H. pylori Infections Market Insights report includes a comprehensive understanding of current treatment practices, H. pylori infections emerging drugs, market share of individual therapies

    3/4/26 5:46:00 PM ET
    $CPIX
    $PHAT
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight

    LAS VEGAS, March 2, 2026 /PRNewswire/ -- The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/OHARA Pharmaceutical), Tovecimig (CTX-009) (Compass Therapeutics), Lenvatinib mesylate (LENVIMA) (Merck/Eisai), and others will further boost the market growth. Recently published Biliary Tract Cancer Market Insights report includes a comprehensive understanding of current

    3/2/26 5:31:00 PM ET
    $BOLD
    $CMPX
    $INCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Commercial Physical & Biological Resarch

    $BTTX
    $CWBR
    $CYTO
    $EIGR
    Leadership Updates

    Live Leadership Updates

    View All

    Tharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer

    Leadership Expansion Supports Execution of Canton Network Infrastructure Strategy Former DRW and Citadel Leader Joins as COO to Drive Institutional Platform Expansion NEW YORK, Feb. 6, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Mark Wendland, Chief Executive Officer, as Chairman of the Board and approved the appointment of Angela Radkowski as Chief Operating Officer, effective February 5, 2026. Mr. Wendland succeeds Vincent LoPriore, wh

    2/6/26 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tharimmune Elects Jill Sommers and William Wiley to Board of Directors

    New Directors Strengthen Governance as Company Advances Canton Network Infrastructure Former CFTC Commissioner Jill Sommers Brings Decades of Regulatory and Public Policy Experience DRW Chief of Staff William Wiley, CFA, Adds Extensive Leadership Experience Across Capital Markets and Global Operations NEW YORK, Feb. 2, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Jill Sommers and William Wiley, CFA, to the Board, effective February 1, 20

    2/2/26 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SenesTech Announces CEO Transition Plan

    Board To Initiate Search For New Leadership As Current CEO Plans Retirement Dr. Jamie Bechtel Named Interim Executive Chair To Further Support Transition PHOENIX, Jan. 28, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a pioneer in fertility control solutions for managing rodent populations, today announced that Joel Fruendt, President and Chief Executive Officer, has informed the Board of Directors of his intent to retire. The Board will commence a formal search for a successor. Mr. Fruendt will continue to serve as President and CEO until the search is completed or until June 30, 2026, whichever occurs first.

    1/28/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $BTTX
    $CWBR
    $CYTO
    $EIGR
    Financials

    Live finance-specific insights

    View All

    SenesTech to Report Fourth Quarter and Fiscal Year 2025 Financial Results on Thursday, March 12, 2026

    Financial results to be released after market close; Conference call to be conducted at 5:00 p.m. Eastern timePHOENIX, March 9, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, will report financial results for its fourth quarter and fiscal year 2025, ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Company has scheduled a conference call that same day, Thursday, March 12, 2026, at 5:00 pm ET, to review the results. Fourth Quarter and Fiscal Year 2024 Conference Call DetailsDa

    3/9/26 4:15:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech Reports Third Quarter 2025 Financial Results with Record Revenue and Adjusted EBITDA

    77% Revenue Growth in Evolve® Rodent Birth Control™ Products Strong Cash Balance and Progress Toward Profitability SURPRISE, Ariz., Nov. 10, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), the leader in fertility control for managing animal pest populations and the only manufacturer of EPA-compliant Rodent Birth Control™ products today announced its financial results for the third quarter ended September 30, 2025. Q3 2025 Financial Highlights Revenues increased by 43% to $690,000, a record for the Company, from $482,000 in Q3 2024.Evolve® Rodent Birth Control product sales

    11/10/25 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    SenesTech to Report Third Quarter 2025 Financial Results on Monday, November 10, 2025

    Financial results to be released after market close; Conference call to be conducted at 5:00 p.m. Eastern time PHOENIX, Nov. 3, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), the leader in fertility control for pest management, will report third quarter 2025 financial results for the period ended September 30, 2025, after the market close on Monday, November 10, 2025. The Company has scheduled a conference call that same day, Monday, November 10, 2025, at 5:00 p.m. Eastern time, to review the results. Third Quarter 2025 Conference Call Details Date and Time: Monday, Novem

    11/3/25 4:15:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $BTTX
    $CWBR
    $CYTO
    $EIGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:28:08 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:12:23 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by Avidity Biosciences Inc.

    SC 13G/A - Avidity Biosciences, Inc. (0001599901) (Subject)

    11/14/24 5:46:11 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care